Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel

Abstract

The activity of ceftaroline was tested against 8233 isolates mainly collected from bloodstream, urinary, respiratory and skin and soft tissue specimens in European medical centers during 2011. This cephalosporin displayed activity against Staphylococcus aureus (MIC₅₀, 0·25 mg/l), with greater activity against MRSA (MIC₅₀, 1 mg/l) than other β-lactams tested. Against Streptococcus pneumoniae, including penicillin-resistant strains, other streptococcal groups and Haemophilus spp., ceftaroline was highly active and MIC90 values ranged from ≤0·015 to 0·12 mg/l. Ceftaroline, like other cephalosporins, had limited activity against ESBL-phenotype Enterobacteriaceae, but showed good activity against isolates not displaying an ESBL-phenotype. Ceftaroline remains very active against MRSA and other organisms than could be associated with its approved indications in the EU (complicated skin and soft tissue infections and community-acquired pneumonia).

Keywords:

• Ceftaroline
• MRSA
• Europe
• Surveillance

Acknowledgements

We wish to express our appreciation to S. Benning, J. Streit, and M. Stilwell in the preparation of this manuscript and to the JMI staff members for scientific and technical assistance in performing this study. This study at JMI Laboratories was supported by an Educational/Research Grant from AstraZeneca, and JMI Laboratories received compensation fees for services in relation to preparing the manuscript, which was funded by AstraZeneca.

JMI Laboratories, Inc. has received research and educational grants in 2010–2013 from Aires, American Proficiency Institute (API), Anacor, Astellas, AstraZeneca, Bayer, bioMerieux, Cempra, Cerexa, Contrafect, Cubist, Dipexium, Furiex, GlaxoSmithKline, Johnson & Johnson (J and J), LegoChem Biosciences Inc., Meiji Seika Kaisha, Merck, Nabriva, Novartis, Pfizer, PPD Therapeutics, Premier Research Group, Rempex, Rib-X Pharmaceuticals, Seachaid, Shionogi, The Medicines Co., Theravance, and ThermoFisher Scientific. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, J&J, and Theravance. In regard to speakers bureaus and stock options – none to declare.